{"id":131287,"date":"2021-09-02T08:00:00","date_gmt":"2021-09-02T08:00:00","guid":{"rendered":"https:\/\/icrowdnewswire.com\/?p=2908113"},"modified":"2021-09-02T08:00:00","modified_gmt":"2021-09-02T08:00:00","slug":"hunter-syndrome-pipeline-analysis-therapeutic-assessment-emerging-therapies-treatment-algorithm-clinical-and-non-clinical-studies-key-companies-includes-avro-bio-regenxbio-jcr-pharma","status":"publish","type":"post","link":"https:\/\/ipsnews.net\/business\/2021\/09\/02\/hunter-syndrome-pipeline-analysis-therapeutic-assessment-emerging-therapies-treatment-algorithm-clinical-and-non-clinical-studies-key-companies-includes-avro-bio-regenxbio-jcr-pharma\/","title":{"rendered":"Hunter Syndrome Pipeline Analysis \u2013 Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, Clinical and Non-Clinical Studies | Key Companies includes AVRO Bio, Regenxbio, JCR Pharma, Denali and Others"},"content":{"rendered":"<p><img decoding=\"async\" width=\"300\" height=\"300\" src=\"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/05\/5353-Delveinsight.png\" class=\"webfeedsFeaturedVisual wp-post-image\" alt=\"\" loading=\"lazy\" style=\"display: block; margin-bottom: 5px; clear:both;max-width: 100%;\" link_thumbnail=\"\" \/><\/p>\n<p><span style=\"font-weight: 400;\"><img decoding=\"async\" loading=\"lazy\" src=\"https:\/\/beta-kiosk.icrowdnewswire.com\/assets\/source\/users\/delveinsight\/Hunter-Syndrome-Pipeline.jpg?1630560320588\" alt=\"Hunter-Syndrome-Pipeline\" width=\"684\" height=\"359\" \/><\/span><\/p>\n<p><span style=\"font-weight: 400;\">DelveInsight&rsquo;s <\/span><strong>Hunter Syndrome Pipeline Insights<\/strong><span style=\"font-weight: 400;\"> report provides a comprehensive outlook of the pipeline therapies that are in different clinical and preclinical stages of development, their launch, and how the market is expected to transform in the aftermath across the Hunter Syndrome domain.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">The <\/span><strong>Hunter Syndrome Pipeline Analysis<\/strong><span style=\"font-weight: 400;\"> report offers a 360&deg; view of the therapeutics landscape by development stage, product type, route of administration, molecule type, and MOA for Hunter Syndrome emerging therapies. The pipeline report lays down the business opportunities, threats, prospective collaborations, strong competitors, and growth strategies.&nbsp;<\/span><\/p>\n<p><strong>Some of the key highlights from the <\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/hunter-syndrome-pipeline-insight?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\" rel=\"noopener\"><strong>Hunter Syndrome Pipeline<\/strong><\/a><strong> report:<\/strong><\/p>\n<ul>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Globally, some of the key <\/span><strong>companies in the Hunter Syndrome Therapeutics<\/strong><span style=\"font-weight: 400;\"> Landscape include <\/span><strong>JCR Pharmaceuticals, Denali Therapeutics, AVRO Bio, Regenxbio,<\/strong><span style=\"font-weight: 400;\"> and several others.&nbsp;<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Hunter Syndrome pipeline is robust and possesses multiple potential drugs in late and mid-stage developments to be launched in the near future. Some of the key <\/span><strong>Hunter Syndrome pipeline therapies<\/strong><span style=\"font-weight: 400;\"> include <\/span><strong>AVR-RD-05, RGX-121, DNL310, JR-141,<\/strong><span style=\"font-weight: 400;\"> and many more.&nbsp;<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Among the different therapies in the Hunter Syndrome pipeline, the <\/span><strong>JCR Pharmaceuticals&rsquo;s JR-141<\/strong><span style=\"font-weight: 400;\"> is in the most advanced stage of development. The company has received Orphan Drug Designation from both the FDA and the EMA. Furthermore, In February 2021, FDA granted Fast Track Designation to the drug and also granted IND clearance to initiate our global Phase III trial of JR-141 in the US.&nbsp;<\/span><\/li>\n<li style=\"font-weight: 400;\"><strong>Denali Therapeutics<\/strong><span style=\"font-weight: 400;\"> is developing <\/span><strong>DNL310<\/strong><span style=\"font-weight: 400;\">, a recombinant IDS enzyme engineered to cross the blood-brain barrier and to replace the IDS enzyme, and treat neuropathic and systemic forms of the disease. In March 2021, Denali Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to (DNL310) for the treatment of patients with Hunter syndrome (MPS II).<\/span><\/li>\n<li style=\"font-weight: 400;\"><strong>Regenxbio <\/strong><span style=\"font-weight: 400;\">is working on <\/span><strong>RGX-121<\/strong><span style=\"font-weight: 400;\">,&nbsp; an investigational gene therapy product candidate for the treatment of Mucopolysaccharidosis Type II. In August 2016, Regenxbio announced that the U.S. Food and Drug Administration (FDA) has granted <\/span><strong>Rare Pediatric Disease Designation to RGX-121<\/strong><span style=\"font-weight: 400;\">.<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Gene therapy is also expected to provide a new dimension to the <\/span><strong>Hunter Syndrome treatment<\/strong><span style=\"font-weight: 400;\">.&nbsp; The gene therapies that can target and subsequently edit specific stretches of a genetic code can also prove to be a big competition in near future for ERT-based therapies.<\/span><\/li>\n<\/ul>\n<p><span style=\"font-weight: 400;\">Request for Sample @ <\/span><a href=\"https:\/\/www.delveinsight.com\/sample-request\/hunter-syndrome-pipeline-insight?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\" rel=\"noopener\"><strong>Hunter Syndrome Pipeline Insights and Outlook<\/strong><\/a><\/p>\n<p><span style=\"font-weight: 400;\">Hunter syndrome, or mucopolysaccharidosis type II (MPS II), is a rare genetic disorder that results in large sugar molecules called glycosaminoglycans (or GAGs or mucopolysaccharides) build up in body tissues. Elaprase is the first and only treatment approved for people suffering from Hunter syndrome. Currently, several companies are diligently involved in developing the Hunter Syndrome therapies.<\/span><\/p>\n<p><a href=\"https:\/\/www.delveinsight.com\/report-store\/hunter-syndrome-pipeline-insight?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\" rel=\"noopener\"><strong>Hunter Syndrome Drug Profile&nbsp;<\/strong><\/a><\/p>\n<ul>\n<li>AVR-RD-05<\/li>\n<li>RGX-121<\/li>\n<li>DNL310<\/li>\n<li>JR-141<\/li>\n<\/ul>\n<p><strong>Key Companies in Hunter Syndrome Therapeutics Landscape<\/strong><\/p>\n<ul>\n<li>AVRO Bio<\/li>\n<li>Regenxbio<\/li>\n<li>JCR Pharmaceuticals&nbsp;<\/li>\n<li>Denali Therapeutics<\/li>\n<\/ul>\n<p><a href=\"https:\/\/www.delveinsight.com\/report-store\/hunter-syndrome-pipeline-insight?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\" rel=\"noopener\"><strong>Hunter Syndrome Pipeline Therapeutics Assessment<\/strong><\/a><\/p>\n<p><strong>By Product Type<\/strong><\/p>\n<ul>\n<li>Mono<\/li>\n<li>Combination<\/li>\n<li>Mono\/Combination<\/li>\n<\/ul>\n<p><strong>By Stage<\/strong><\/p>\n<ul style=\"list-style-type: disc;\">\n<li><span style=\"font-weight: 400;\">Discovery&nbsp;<\/span><\/li>\n<li><span style=\"font-weight: 400;\">Pre-clinical<\/span><\/li>\n<li><span style=\"font-weight: 400;\">Phase I<\/span><\/li>\n<li><span style=\"font-weight: 400;\">Phase II<\/span><\/li>\n<li><span style=\"font-weight: 400;\">Phase III<\/span><\/li>\n<li><span style=\"font-weight: 400;\">Pre-registration&nbsp;<\/span><\/li>\n<\/ul>\n<p><strong>By Route of Administration<\/strong><\/p>\n<ul>\n<li>Subcutaneous<\/li>\n<li>Intravenous<\/li>\n<li>Intramuscular<\/li>\n<\/ul>\n<p><strong>By Molecule Type<\/strong><\/p>\n<ul style=\"list-style-type: disc;\">\n<li>Recombinant fusion proteins<\/li>\n<li>Gene therapies<\/li>\n<li>Enzymes<\/li>\n<li>Product Type<\/li>\n<\/ul>\n<p><strong>By Mechanism of Action&nbsp;<\/strong><\/p>\n<ul>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Iduronate Sulfatase Replacements<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Gene transference<\/span><\/li>\n<\/ul>\n<p><strong>Got queries? Reach out for more information @ <\/strong><a href=\"https:\/\/www.delveinsight.com\/sample-request\/hunter-syndrome-pipeline-insight?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\" rel=\"noopener\"><strong>Hunter Syndrome Drug Pipeline Assessment<\/strong><\/a><\/p>\n<p><strong>Scope of the Report<\/strong><\/p>\n<ul>\n<li style=\"font-weight: 400;\"><strong>Coverage: <\/strong><span style=\"font-weight: 400;\">Global<\/span><\/li>\n<li style=\"font-weight: 400;\"><strong>Key Market Players: <\/strong>AVRO Bio, Regenxbio, JCR Pharmaceuticals, Denali Therapeutics, and others.<\/li>\n<li style=\"font-weight: 400;\"><strong>Key Pipeline Therapies:<\/strong> AVR-RD-05, RGX-121, DNL310, JR-141, and several others.<\/li>\n<\/ul>\n<p><strong>Table of Content&nbsp;<\/strong><\/p>\n<table>\n<tbody>\n<tr>\n<td>\n<p><span style=\"font-weight: 400;\">1<\/span><\/p>\n<\/td>\n<td>\n<p><span style=\"font-weight: 400;\">Report Introduction<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><span style=\"font-weight: 400;\">2<\/span><\/p>\n<\/td>\n<td>\n<p><span style=\"font-weight: 400;\">Hunter Syndrome&nbsp;<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><span style=\"font-weight: 400;\">3<\/span><\/p>\n<\/td>\n<td>\n<p><span style=\"font-weight: 400;\">Hunter Syndrome Current Treatment Patterns<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><span style=\"font-weight: 400;\">4<\/span><\/p>\n<\/td>\n<td>\n<p><span style=\"font-weight: 400;\">Hunter Syndrome &#8211; DelveInsight&#8217;s Analytical Perspective<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><span style=\"font-weight: 400;\">5<\/span><\/p>\n<\/td>\n<td>\n<p><span style=\"font-weight: 400;\">Therapeutic Assessment<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><span style=\"font-weight: 400;\">6<\/span><\/p>\n<\/td>\n<td>\n<p><span style=\"font-weight: 400;\">Hunter Syndrome Late Stage Products (Phase-III)<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><span style=\"font-weight: 400;\">7<\/span><\/p>\n<\/td>\n<td>\n<p><span style=\"font-weight: 400;\">Hunter Syndrome Mid Stage Products (Phase-II)<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><span style=\"font-weight: 400;\">8<\/span><\/p>\n<\/td>\n<td>\n<p><span style=\"font-weight: 400;\">Early Stage Hunter Syndrome Products (Phase-I)<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><span style=\"font-weight: 400;\">9<\/span><\/p>\n<\/td>\n<td>\n<p><span style=\"font-weight: 400;\">Hunter Syndrome Pre-clinical Products and Discovery Stage Products<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><span style=\"font-weight: 400;\">10<\/span><\/p>\n<\/td>\n<td>\n<p><span style=\"font-weight: 400;\">Inactive Products<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><span style=\"font-weight: 400;\">11<\/span><\/p>\n<\/td>\n<td>\n<p><span style=\"font-weight: 400;\">Dormant Products<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><span style=\"font-weight: 400;\">12<\/span><\/p>\n<\/td>\n<td>\n<p><span style=\"font-weight: 400;\">Hunter Syndrome Discontinued Products<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><span style=\"font-weight: 400;\">13<\/span><\/p>\n<\/td>\n<td>\n<p><span style=\"font-weight: 400;\">Hunter Syndrome Product Profiles<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><span style=\"font-weight: 400;\">14<\/span><\/p>\n<\/td>\n<td>\n<p><span style=\"font-weight: 400;\">Hunter Syndrome Key Companies<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><span style=\"font-weight: 400;\">15<\/span><\/p>\n<\/td>\n<td>\n<p><span style=\"font-weight: 400;\">Hunter Syndrome Key Products<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><span style=\"font-weight: 400;\">16<\/span><\/p>\n<\/td>\n<td>\n<p><span style=\"font-weight: 400;\">Dormant and Discontinued Products<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><span style=\"font-weight: 400;\">17<\/span><\/p>\n<\/td>\n<td>\n<p><span style=\"font-weight: 400;\">Hunter Syndrome Unmet Needs<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><span style=\"font-weight: 400;\">18<\/span><\/p>\n<\/td>\n<td>\n<p><span style=\"font-weight: 400;\">Hunter Syndrome Future Perspectives<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><span style=\"font-weight: 400;\">19<\/span><\/p>\n<\/td>\n<td>\n<p><span style=\"font-weight: 400;\">Hunter Syndrome Analyst Review<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><span style=\"font-weight: 400;\">20<\/span><\/p>\n<\/td>\n<td>\n<p><span style=\"font-weight: 400;\">Appendix<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p><span style=\"font-weight: 400;\">21<\/span><\/p>\n<\/td>\n<td>\n<p><span style=\"font-weight: 400;\"> Report Methodology<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><span style=\"font-weight: 400;\">Know more of what&rsquo;s covered in the <\/span><a href=\"https:\/\/www.delveinsight.com\/sample-request\/hunter-syndrome-pipeline-insight?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\" rel=\"noopener\"><strong>Hunter Syndrome Pipeline Assessment<\/strong><\/a><span style=\"font-weight: 400;\"> report<\/span><\/p>\n<p><strong>Key Questions Answered in the Hunter Syndrome Report<\/strong><\/p>\n<ul>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">What are the current options for Hunter Syndrome treatment?<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">How many companies are developing therapies for the treatment of Hunter Syndrome?&nbsp;<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">What are the principal therapies developed by these companies in the industry?<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">How many therapies are developed by each company for the treatment of Hunter Syndrome?<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">How many Hunter Syndrome emerging therapies are in early-stage, mid-stage, and late stage of development for the treatment of Hunter Syndrome?<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Out of total pipeline products, how many therapies are given as a monotherapy and in combination with other therapies?&nbsp;<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and major licensing activities that will impact the Hunter Syndrome market?&nbsp;<\/span><\/li>\n<\/ul>\n<p><span style=\"font-weight: 400;\">Request for a Webex demo @ <\/span><a href=\"https:\/\/www.delveinsight.com\/sample-request\/hunter-syndrome-pipeline-insight?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\" rel=\"noopener\"><strong>Hunter Syndrome Drug Pipeline<\/strong><\/a><span style=\"font-weight: 400;\"> and get a walk-through of our report&nbsp;<\/span><\/p>\n<p><strong>Latest Reports<\/strong><\/p>\n<p><strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/hunter-syndrome-market?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\" rel=\"noopener\">Hunter Syndrome Market Insight<\/a><\/strong><\/p>\n<p><span style=\"font-weight: 400;\">DelveInsight&rsquo;s &lsquo;Hunter Syndrome -Market Insights, Epidemiology and Market Forecast&ndash; 2030&rsquo; report delivers an in-depth understanding of the Hunter Syndrome, historical and forecasted epidemiology as well as the Hunter Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/span><\/p>\n<p><strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/hunter-syndrome-epidemiology-forecast?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\" rel=\"noopener\">Hunter Syndrome Epidemiology Forecast<\/a><\/strong><\/p>\n<p>DelveInsight&rsquo;s &lsquo;Hunter Syndrome &#8211; Epidemiology Forecast&ndash;2030&rsquo; report delivers an in-depth understanding of the disease, historical and forecasted Hunter Syndrome epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.&nbsp;<\/p>\n<p><strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/corneal-endothelial-dystrophy-market\" target=\"_blank\" rel=\"noopener\">Corneal Endothelial Dystrophy Market<\/a><\/strong><\/p>\n<p>DelveInsight&#8217;s &#8220;Corneal Endothelial Dystrophy Market Insights, Epidemiology, and Market Forecast 2030&#8221; report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Corneal Endothelial Dystrophy market size and shares analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).<\/p>\n<p><a style=\"font-weight: bold;\" href=\"https:\/\/www.delveinsight.com\/report-store\/global-kinase-inhibitor-in-autoimmune-diseases-market\" target=\"_blank\" rel=\"noopener\">Global Kinase Inhibitor in Autoimmune Diseases Market<\/a><\/p>\n<p><span style=\"font-weight: 400;\">DelveInsight&#8217;s &#8220;Global Kinase Inhibitor in Autoimmune Diseases&nbsp; Market Insights, Epidemiology, and Market Forecast 2030&#8221; report delivers an in-depth understanding of the Global Kinase Inhibitor in Autoimmune Diseases market size, shares and trends analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).<\/span><\/p>\n<p><a href=\"https:\/\/www.delveinsight.com\/report-store\/wasting-syndrome-market\" target=\"_blank\" rel=\"noopener\"><strong>Muscle Atrophy\/ Wasting Syndrome Market&nbsp;<\/strong><\/a><\/p>\n<p><span style=\"font-weight: 400;\">DelveInsight&#8217;s &#8220;Muscle Atrophy\/ Wasting Syndrome Market Insights, Epidemiology, and Market Forecast 2030&#8221; report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Muscle Atrophy\/ Wasting Syndrome market size and shares analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).<\/span><\/p>\n<p><strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/pars-plantis-market\" target=\"_blank\" rel=\"noopener\">Pars Plantis Market Insight<\/a><\/strong><\/p>\n<p><span style=\"font-weight: 400;\">DelveInsight&#8217;s &#8220;Pars Plantis Market Insights, Epidemiology, and Market Forecast 2030&#8221; report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Pars Plantis market size and shares analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).<\/span><\/p>\n<p><a href=\"https:\/\/www.delveinsight.com\/report-store\/nicotine-addiction-market\" target=\"_blank\" rel=\"noopener\"><strong>Nicotine Addiction Market<\/strong><\/a><\/p>\n<p><span style=\"font-weight: 400;\">DelveInsight&rsquo;s &ldquo;Nicotine Addiction Market Insights, Epidemiology and Market Forecast 2030&rdquo; report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Nicotine Addiction market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/span><\/p>\n<p><strong>Healthcare Blogs By DelveInsight<\/strong><\/p>\n<ul>\n<li><strong>&nbsp;<\/strong><a href=\"https:\/\/www.delveinsight.com\/blog\/key-companies-in-neurological-disorders-market\" target=\"_blank\" rel=\"noopener\"><strong>Neurological Disease Therapy Market<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/www.delveinsight.com\/blog\/biomarkers-in-non-small-cell-lung-cancer-therapy-market\" target=\"_blank\" rel=\"noopener\"><strong>Non-small Cell Lung Cancer Therapy Market<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/www.delveinsight.com\/blog\/primary-hyperoxaluria-market\" target=\"_blank\" rel=\"noopener\"><strong>Primary Hyperoxaluria Market Clinical Trials<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/www.delveinsight.com\/blog\/crohns-disease-market\/?utm_source=blog&amp;utm_medium=promotion&amp;utm_campaign=blog\" target=\"_blank\" rel=\"noopener\"><strong>Crohn&rsquo;s Disease Treatment Market<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/www.delveinsight.com\/blog\/leading-companies-in-the-musculoskeletal-disorders-market\/?utm_source=blog&amp;utm_medium=promotion&amp;utm_campaign=blog\" target=\"_blank\" rel=\"noopener\"><strong>Leading Musculoskeletal Disorders and Key Companies<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/www.delveinsight.com\/blog\/peanut-allergy-market?utm_source=blog&amp;utm_medium=promotion&amp;utm_campaign=blog\" target=\"_blank\" rel=\"noopener\"><strong>Peanut Allergy Therapy Market&nbsp;<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/www.delveinsight.com\/blog\/transcranial-stimulation-devices-market\/?utm_source=blog&amp;utm_medium=promotion&amp;utm_campaign=blog\" target=\"_blank\" rel=\"noopener\"><strong>Key Companies in the Transcranial Stimulation Devices Market&nbsp;<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/www.delveinsight.com\/blog\/uncomplicated-urinary-tract-infections-market\/?utm_source=blog&amp;utm_medium=promotion&amp;utm_campaign=blog\" target=\"_blank\" rel=\"noopener\"><strong>Uncomplicated Urinary Tract Infections Market Size<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/www.delveinsight.com\/blog\/leading-companies-in-autoimmune-diseases-market\/?utm_source=blog&amp;utm_medium=promotion&amp;utm_campaign=blog\" target=\"_blank\" rel=\"noopener\"><strong>Autoimmune Diseases Treatment Landscape<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/www.delveinsight.com\/blog\/insulin-delivery-devices-market\/?utm_source=blog&amp;utm_medium=promotion&amp;utm_campaign=blog\" target=\"_blank\" rel=\"noopener\"><strong>Insulin Delivery Devices Market Size<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/www.delveinsight.com\/blog\/femtech-market\/?utm_source=blog&amp;utm_medium=promotion&amp;utm_campaign=blog\" target=\"_blank\" rel=\"noopener\"><strong>Companies in FemTech Market<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/www.delveinsight.com\/blog\/skin-cancer-treatment-market-and-key-companies\/?utm_source=blog&amp;utm_medium=promotion&amp;utm_campaign=blog\" target=\"_blank\" rel=\"noopener\"><strong>Common Types of Skin Cancers<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/www.delveinsight.com\/blog\/cardiac-monitoring-devices-market\/?utm_source=blog&amp;utm_medium=promotion&amp;utm_campaign=blog\" target=\"_blank\" rel=\"noopener\"><strong>Key Companies in Cardiac Monitoring Devices Market<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/www.delveinsight.com\/blog\/jak-inhibitors-market\/?utm_source=blog&amp;utm_medium=promotion&amp;utm_campaign=blog\" target=\"_blank\" rel=\"noopener\"><strong>Janus Kinase Inhibitors Market<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/www.delveinsight.com\/blog\/technological-innovations-in-healthcare?utm_source=blog&amp;utm_medium=promotion&amp;utm_campaign=blog\" target=\"_blank\" rel=\"noopener\"><strong>Technological Innovation in Healthcare<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/www.delveinsight.com\/blog\/von-hippel-lindau-market?utm_source=blog&amp;utm_medium=promotion&amp;utm_campaign=blog\" target=\"_blank\" rel=\"noopener\"><strong>Von Hippel-Lindau Market&nbsp;<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/www.delveinsight.com\/blog\/fecal-incontinence-market?utm_source=blog&amp;utm_medium=promotion&amp;utm_campaign=blog\" target=\"_blank\" rel=\"noopener\"><strong>Fecal Incontinence Therapy Market<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/www.delveinsight.com\/blog\/advances-in-diabetes-care-and-management?utm_source=blog&amp;utm_medium=promotion&amp;utm_campaign=blog\" target=\"_blank\" rel=\"noopener\"><strong>Advances in the Management of Diabetes<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/www.delveinsight.com\/blog\/major-depressive-disorder?utm_source=blog&amp;utm_medium=promotion&amp;utm_campaign=blog\" target=\"_blank\" rel=\"noopener\"><strong>Major Depressive Disorder Treatment Market<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/www.delveinsight.com\/blog\/virtual-clinical-trials?utm_source=blog&amp;utm_medium=promotion&amp;utm_campaign=blog\" target=\"_blank\" rel=\"noopener\"><strong>Virtual Clinical Trials Future outlook<\/strong><\/a><\/li>\n<li><strong><a href=\"https:\/\/www.delveinsight.com\/blog\/drones-in-healthcare\" target=\"_blank\" rel=\"noopener\">Drones in Healthcare Sector<\/a><\/strong><\/li>\n<li><a href=\"https:\/\/www.delveinsight.com\/blog\/venous-thromboembolism\" target=\"_blank\" rel=\"noopener\"><strong>Venous Thromboembolism Treatment Market<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/www.delveinsight.com\/blog\/duchenne-muscular-dystrophy-market\" target=\"_blank\" rel=\"noopener\"><strong>Duchenne Muscular Dystrophy Therapeutics Market<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/www.delveinsight.com\/blog\/top-pharma-companies-by-revenue\" target=\"_blank\" rel=\"noopener\"><strong>Top Pharmaceutical Companies in the World<\/strong><\/a><\/li>\n<\/ul>\n<p><strong>About <\/strong><a href=\"https:\/\/www.delveinsight.com\/?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\" rel=\"noopener\"><strong>DelveInsight<\/strong><\/a><br \/><span style=\"font-weight: 400;\">DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.&nbsp; Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform <\/span><a href=\"https:\/\/www.delveinsight.com\/pharmdelve?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\" rel=\"noopener\"><strong>PharmDelve<\/strong><\/a><span style=\"font-weight: 400;\">.<\/span><\/p>\n<p><strong>Connect With Us at <\/strong><a href=\"https:\/\/www.linkedin.com\/company\/delveinsight-business-research-llp\/\" target=\"_blank\" rel=\"noopener\"><strong>LinkedIn<\/strong><\/a><strong> |<\/strong><a href=\"https:\/\/www.facebook.com\/delveinsightindia\/\" target=\"_blank\" rel=\"noopener\"><strong> Facebook<\/strong><\/a><strong> |<\/strong><a href=\"https:\/\/twitter.com\/delve_insight\" target=\"_blank\" rel=\"noopener\"><strong> Twitter<\/strong><\/a><\/p>\n<p class=\"tags\">Tags: <a href=\"https:\/\/icrowdnewswire.com\/tag\/hunter-syndrome-pipeline\/\" rel=\"tag noopener\" target=\"_blank\">Hunter Syndrome Pipeline<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/tag\/hunter-syndrome-market\/\" rel=\"tag noopener\" target=\"_blank\">Hunter Syndrome Market<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/tag\/hunter-syndrome\/\" rel=\"tag noopener\" target=\"_blank\">Hunter Syndrome<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/tag\/hunter-syndrome-epidemiology\/\" rel=\"tag noopener\" target=\"_blank\">Hunter Syndrome Epidemiology<\/a> <\/p>\n<div><strong>See Campaign: <\/strong><a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"noopener\">https:\/\/www.delveinsight.com\/<\/a><br \/><b>Contact Information:<\/b><br \/>Shruti Thakur\u00a0 info@delveinsight.com\u00a0 +1(919)321-6187<\/p>\n<p><b>Tags:<\/b><br \/><a href=\"https:\/\/icrowdnewswire.com\/category\/pr-wirein\/\" rel=\"category tag noopener\" target=\"_blank\">PR-Wirein<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/category\/menafn\/\" rel=\"category tag noopener\" target=\"_blank\">Menafn<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/category\/ips\/\" rel=\"category tag noopener\" target=\"_blank\">IPS<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/category\/reportedtimes\/\" rel=\"category tag noopener\" target=\"_blank\">Reportedtimes<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/category\/news-category\/extended-distribution\/\" rel=\"category tag noopener\" target=\"_blank\">Extended Distribution<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/category\/news-category\/icn-internal-distribution\/\" rel=\"category tag noopener\" target=\"_blank\">iCN Internal Distribution<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/category\/news-category\/research-newswire\/\" rel=\"category tag noopener\" target=\"_blank\">Research Newswire<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/category\/language\/english\/\" rel=\"category tag noopener\" target=\"_blank\">English<\/a><\/p>\n<\/div>\n<div>\n<h3>Contact Information:<\/h3>\n<p>Shruti Thakur\u00a0 info@delveinsight.com\u00a0 +1(919)321-6187<\/p>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight&rsquo;s Hunter Syndrome Pipeline Insights report provides a comprehensive outlook of the pipeline therapies that are in different clinical and preclinical stages of development, their launch, and how the market is expected to transform in the aftermath across the Hunter Syndrome domain. The Hunter Syndrome Pipeline Analysis report offers a 360&deg; view of the therapeutics [&hellip;] <a href=\"https:\/\/ipsnews.net\/business\/2021\/09\/02\/hunter-syndrome-pipeline-analysis-therapeutic-assessment-emerging-therapies-treatment-algorithm-clinical-and-non-clinical-studies-key-companies-includes-avro-bio-regenxbio-jcr-pharma\/\" class=\"more-link\">Continue Reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":291,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[20],"tags":[],"class_list":["post-131287","post","type-post","status-publish","format-standard","hentry","category-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.9 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Hunter Syndrome Pipeline Analysis \u2013 Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, Clinical and Non-Clinical Studies | Key Companies includes AVRO Bio, Regenxbio, JCR Pharma, Denali and Others - Business<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"http:\/\/ipsnews.net\/business\/2021\/09\/02\/hunter-syndrome-pipeline-analysis-therapeutic-assessment-emerging-therapies-treatment-algorithm-clinical-and-non-clinical-studies-key-companies-includes-avro-bio-regenxbio-jcr-pharma\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hunter Syndrome Pipeline Analysis \u2013 Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, Clinical and Non-Clinical Studies | Key Companies includes AVRO Bio, Regenxbio, JCR Pharma, Denali and Others - Business\" \/>\n<meta property=\"og:description\" content=\"DelveInsight&rsquo;s Hunter Syndrome Pipeline Insights report provides a comprehensive outlook of the pipeline therapies that are in different clinical and preclinical stages of development, their launch, and how the market is expected to transform in the aftermath across the Hunter Syndrome domain. The Hunter Syndrome Pipeline Analysis report offers a 360&deg; view of the therapeutics [&hellip;] Continue Reading &rarr;\" \/>\n<meta property=\"og:url\" content=\"http:\/\/ipsnews.net\/business\/2021\/09\/02\/hunter-syndrome-pipeline-analysis-therapeutic-assessment-emerging-therapies-treatment-algorithm-clinical-and-non-clinical-studies-key-companies-includes-avro-bio-regenxbio-jcr-pharma\/\" \/>\n<meta property=\"og:site_name\" content=\"Business\" \/>\n<meta property=\"article:published_time\" content=\"2021-09-02T08:00:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/05\/5353-Delveinsight.png\" \/>\n<meta name=\"author\" content=\"iCrowdNewswire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"iCrowdNewswire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"http:\/\/ipsnews.net\/business\/2021\/09\/02\/hunter-syndrome-pipeline-analysis-therapeutic-assessment-emerging-therapies-treatment-algorithm-clinical-and-non-clinical-studies-key-companies-includes-avro-bio-regenxbio-jcr-pharma\/\",\"url\":\"http:\/\/ipsnews.net\/business\/2021\/09\/02\/hunter-syndrome-pipeline-analysis-therapeutic-assessment-emerging-therapies-treatment-algorithm-clinical-and-non-clinical-studies-key-companies-includes-avro-bio-regenxbio-jcr-pharma\/\",\"name\":\"Hunter Syndrome Pipeline Analysis \u2013 Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, Clinical and Non-Clinical Studies | Key Companies includes AVRO Bio, Regenxbio, JCR Pharma, Denali and Others - Business\",\"isPartOf\":{\"@id\":\"https:\/\/ipsnews.net\/business\/#website\"},\"primaryImageOfPage\":{\"@id\":\"http:\/\/ipsnews.net\/business\/2021\/09\/02\/hunter-syndrome-pipeline-analysis-therapeutic-assessment-emerging-therapies-treatment-algorithm-clinical-and-non-clinical-studies-key-companies-includes-avro-bio-regenxbio-jcr-pharma\/#primaryimage\"},\"image\":{\"@id\":\"http:\/\/ipsnews.net\/business\/2021\/09\/02\/hunter-syndrome-pipeline-analysis-therapeutic-assessment-emerging-therapies-treatment-algorithm-clinical-and-non-clinical-studies-key-companies-includes-avro-bio-regenxbio-jcr-pharma\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/05\/5353-Delveinsight.png\",\"datePublished\":\"2021-09-02T08:00:00+00:00\",\"author\":{\"@id\":\"https:\/\/ipsnews.net\/business\/#\/schema\/person\/bde271d5882ffdcb71d1a2a961b51fee\"},\"breadcrumb\":{\"@id\":\"http:\/\/ipsnews.net\/business\/2021\/09\/02\/hunter-syndrome-pipeline-analysis-therapeutic-assessment-emerging-therapies-treatment-algorithm-clinical-and-non-clinical-studies-key-companies-includes-avro-bio-regenxbio-jcr-pharma\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"http:\/\/ipsnews.net\/business\/2021\/09\/02\/hunter-syndrome-pipeline-analysis-therapeutic-assessment-emerging-therapies-treatment-algorithm-clinical-and-non-clinical-studies-key-companies-includes-avro-bio-regenxbio-jcr-pharma\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"http:\/\/ipsnews.net\/business\/2021\/09\/02\/hunter-syndrome-pipeline-analysis-therapeutic-assessment-emerging-therapies-treatment-algorithm-clinical-and-non-clinical-studies-key-companies-includes-avro-bio-regenxbio-jcr-pharma\/#primaryimage\",\"url\":\"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/05\/5353-Delveinsight.png\",\"contentUrl\":\"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/05\/5353-Delveinsight.png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"http:\/\/ipsnews.net\/business\/2021\/09\/02\/hunter-syndrome-pipeline-analysis-therapeutic-assessment-emerging-therapies-treatment-algorithm-clinical-and-non-clinical-studies-key-companies-includes-avro-bio-regenxbio-jcr-pharma\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ipsnews.net\/business\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hunter Syndrome Pipeline Analysis \u2013 Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, Clinical and Non-Clinical Studies | Key Companies includes AVRO Bio, Regenxbio, JCR Pharma, Denali and Others\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ipsnews.net\/business\/#website\",\"url\":\"https:\/\/ipsnews.net\/business\/\",\"name\":\"Business\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ipsnews.net\/business\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/ipsnews.net\/business\/#\/schema\/person\/bde271d5882ffdcb71d1a2a961b51fee\",\"name\":\"iCrowdNewswire\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ipsnews.net\/business\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/aa079ec4d87ad6117c9db7a1a2cde1607ee2f869010252c2d0af346f0047b325?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/aa079ec4d87ad6117c9db7a1a2cde1607ee2f869010252c2d0af346f0047b325?s=96&d=mm&r=g\",\"caption\":\"iCrowdNewswire\"},\"sameAs\":[\"https:\/\/heymuse.com\/ips\"],\"url\":\"https:\/\/ipsnews.net\/business\/author\/icrowdnewswire\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Hunter Syndrome Pipeline Analysis \u2013 Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, Clinical and Non-Clinical Studies | Key Companies includes AVRO Bio, Regenxbio, JCR Pharma, Denali and Others - Business","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"http:\/\/ipsnews.net\/business\/2021\/09\/02\/hunter-syndrome-pipeline-analysis-therapeutic-assessment-emerging-therapies-treatment-algorithm-clinical-and-non-clinical-studies-key-companies-includes-avro-bio-regenxbio-jcr-pharma\/","og_locale":"en_US","og_type":"article","og_title":"Hunter Syndrome Pipeline Analysis \u2013 Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, Clinical and Non-Clinical Studies | Key Companies includes AVRO Bio, Regenxbio, JCR Pharma, Denali and Others - Business","og_description":"DelveInsight&rsquo;s Hunter Syndrome Pipeline Insights report provides a comprehensive outlook of the pipeline therapies that are in different clinical and preclinical stages of development, their launch, and how the market is expected to transform in the aftermath across the Hunter Syndrome domain. The Hunter Syndrome Pipeline Analysis report offers a 360&deg; view of the therapeutics [&hellip;] Continue Reading &rarr;","og_url":"http:\/\/ipsnews.net\/business\/2021\/09\/02\/hunter-syndrome-pipeline-analysis-therapeutic-assessment-emerging-therapies-treatment-algorithm-clinical-and-non-clinical-studies-key-companies-includes-avro-bio-regenxbio-jcr-pharma\/","og_site_name":"Business","article_published_time":"2021-09-02T08:00:00+00:00","og_image":[{"url":"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/05\/5353-Delveinsight.png","type":"","width":"","height":""}],"author":"iCrowdNewswire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"iCrowdNewswire","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"http:\/\/ipsnews.net\/business\/2021\/09\/02\/hunter-syndrome-pipeline-analysis-therapeutic-assessment-emerging-therapies-treatment-algorithm-clinical-and-non-clinical-studies-key-companies-includes-avro-bio-regenxbio-jcr-pharma\/","url":"http:\/\/ipsnews.net\/business\/2021\/09\/02\/hunter-syndrome-pipeline-analysis-therapeutic-assessment-emerging-therapies-treatment-algorithm-clinical-and-non-clinical-studies-key-companies-includes-avro-bio-regenxbio-jcr-pharma\/","name":"Hunter Syndrome Pipeline Analysis \u2013 Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, Clinical and Non-Clinical Studies | Key Companies includes AVRO Bio, Regenxbio, JCR Pharma, Denali and Others - Business","isPartOf":{"@id":"https:\/\/ipsnews.net\/business\/#website"},"primaryImageOfPage":{"@id":"http:\/\/ipsnews.net\/business\/2021\/09\/02\/hunter-syndrome-pipeline-analysis-therapeutic-assessment-emerging-therapies-treatment-algorithm-clinical-and-non-clinical-studies-key-companies-includes-avro-bio-regenxbio-jcr-pharma\/#primaryimage"},"image":{"@id":"http:\/\/ipsnews.net\/business\/2021\/09\/02\/hunter-syndrome-pipeline-analysis-therapeutic-assessment-emerging-therapies-treatment-algorithm-clinical-and-non-clinical-studies-key-companies-includes-avro-bio-regenxbio-jcr-pharma\/#primaryimage"},"thumbnailUrl":"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/05\/5353-Delveinsight.png","datePublished":"2021-09-02T08:00:00+00:00","author":{"@id":"https:\/\/ipsnews.net\/business\/#\/schema\/person\/bde271d5882ffdcb71d1a2a961b51fee"},"breadcrumb":{"@id":"http:\/\/ipsnews.net\/business\/2021\/09\/02\/hunter-syndrome-pipeline-analysis-therapeutic-assessment-emerging-therapies-treatment-algorithm-clinical-and-non-clinical-studies-key-companies-includes-avro-bio-regenxbio-jcr-pharma\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["http:\/\/ipsnews.net\/business\/2021\/09\/02\/hunter-syndrome-pipeline-analysis-therapeutic-assessment-emerging-therapies-treatment-algorithm-clinical-and-non-clinical-studies-key-companies-includes-avro-bio-regenxbio-jcr-pharma\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"http:\/\/ipsnews.net\/business\/2021\/09\/02\/hunter-syndrome-pipeline-analysis-therapeutic-assessment-emerging-therapies-treatment-algorithm-clinical-and-non-clinical-studies-key-companies-includes-avro-bio-regenxbio-jcr-pharma\/#primaryimage","url":"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/05\/5353-Delveinsight.png","contentUrl":"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/05\/5353-Delveinsight.png"},{"@type":"BreadcrumbList","@id":"http:\/\/ipsnews.net\/business\/2021\/09\/02\/hunter-syndrome-pipeline-analysis-therapeutic-assessment-emerging-therapies-treatment-algorithm-clinical-and-non-clinical-studies-key-companies-includes-avro-bio-regenxbio-jcr-pharma\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ipsnews.net\/business\/"},{"@type":"ListItem","position":2,"name":"Hunter Syndrome Pipeline Analysis \u2013 Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, Clinical and Non-Clinical Studies | Key Companies includes AVRO Bio, Regenxbio, JCR Pharma, Denali and Others"}]},{"@type":"WebSite","@id":"https:\/\/ipsnews.net\/business\/#website","url":"https:\/\/ipsnews.net\/business\/","name":"Business","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ipsnews.net\/business\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/ipsnews.net\/business\/#\/schema\/person\/bde271d5882ffdcb71d1a2a961b51fee","name":"iCrowdNewswire","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ipsnews.net\/business\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/aa079ec4d87ad6117c9db7a1a2cde1607ee2f869010252c2d0af346f0047b325?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/aa079ec4d87ad6117c9db7a1a2cde1607ee2f869010252c2d0af346f0047b325?s=96&d=mm&r=g","caption":"iCrowdNewswire"},"sameAs":["https:\/\/heymuse.com\/ips"],"url":"https:\/\/ipsnews.net\/business\/author\/icrowdnewswire\/"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/posts\/131287","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/users\/291"}],"replies":[{"embeddable":true,"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/comments?post=131287"}],"version-history":[{"count":1,"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/posts\/131287\/revisions"}],"predecessor-version":[{"id":131288,"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/posts\/131287\/revisions\/131288"}],"wp:attachment":[{"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/media?parent=131287"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/categories?post=131287"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/tags?post=131287"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}